Makarova S I
Institute of Molecular Biology and Biophysics, Siberia Branch of the Russian Academy of Medical Science, Timakova str. 2, Novosibirsk, Russia.
Curr Drug Metab. 2008 Jul;9(6):538-45. doi: 10.2174/138920008784892047.
There are a lot of pharmaceutical substances nowadays on the market. More than 1000 drugs have been implicated in causing liver diseases in more than one occasion. The liver is the most massive and important internal organ of human body. The morphological and functional integrity of the liver is vital to the health of the human organism. Xenobiotic biotransformation is the principal mechanism for maintaining homeostasis during exposure of organisms to small foreign molecules, such as drugs. Most drugs are lipophilic and they become more hydrophilic by xenobiotic metabolizing enzymes. Arylamine N acetyltransferases (NAT) convert aromatic amines or hydrazines to aromatic amides and hydrazides. A lot of generally used drugs contain aromatic amine or hydrazine groups. Drug-induced liver injury (DILI) is the grave problem in the present world. The frequency of DILI is 15-40 cases per 100000 persons per year with 6 % mortality rate on average. This review is devoted to the analyses of arylamine N-acetyltransferases role in DILI. The NAT gene polymorphism and slow phenotype are associated with predisposition to hepatotoxicity during drug-specific treatment. NAT activity is changed by smoking, viral infections and variety of drugs. It is shown that the involving of NAT in pathogenic processes of DILI such as inflammatory or immune response, formation reactive metabolites, oxidative stress, cholestasis.
如今市场上有大量的药物。超过1000种药物曾不止一次被认为会导致肝脏疾病。肝脏是人体最大且最重要的内部器官。肝脏的形态和功能完整性对人体健康至关重要。异生物质生物转化是生物体在接触小分子外来物质(如药物)时维持体内平衡的主要机制。大多数药物是亲脂性的,它们通过异生物质代谢酶变得更具亲水性。芳胺N - 乙酰转移酶(NAT)将芳香胺或肼转化为芳香酰胺和酰肼。许多常用药物含有芳香胺或肼基团。药物性肝损伤(DILI)是当今世界的一个严重问题。DILI的发生率为每年每10万人中有15 - 40例,平均死亡率为6%。本综述致力于分析芳胺N - 乙酰转移酶在DILI中的作用。NAT基因多态性和慢代谢表型与特定药物治疗期间易发生肝毒性有关。吸烟、病毒感染和多种药物会改变NAT活性。研究表明,NAT参与了DILI的致病过程,如炎症或免疫反应、活性代谢产物的形成、氧化应激、胆汁淤积。